Kefah Mokbel: When Does Tumour Shrinkage Peak With T-DXd in HER2-Positive Metastatic Breast Cancer?
Kefah Mokbel/ LinkedIn

Kefah Mokbel: When Does Tumour Shrinkage Peak With T-DXd in HER2-Positive Metastatic Breast Cancer?

Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared on LinkedIn:

“When does tumour shrinkage reach its maximum with trastuzumab deruxtecan (T-DXd), and could that help guide future maintenance strategies?

The TRACE study, published in The Breast, explores this question in HER2-positive metastatic breast cancer.

This retrospective study across three centres in Japan included 93 patients in its primary analysis:

  • Median time to maximal response was 4.57 months (95% CI: 3.73–5.60).
  • Among 56 patients with evaluable imaging, median tumour burden change beyond 18 weeks was −2.7%, although individual trajectories varied substantially.
  • No statistically significant differences in time to maximal response were detected by treatment line or hormone receptor status.

These findings provide a rationale for prospectively studying time-limited T-DXd induction followed by maintenance therapy.

The key distinction: reaching maximal tumour shrinkage does not establish that switching treatment will preserve disease control.

The analysis excluded patients with progression as their best response or stable disease without shrinkage, and most patients received T-DXd in the third line or later. These results are hypothesis-generating, with limited direct applicability to first-line combination treatment.

The median time to maximal shrinkage of 4.57 months suggests that a reassessment around 4–5 months could be a useful research window: evaluate the residual disease distribution, whether response is continuing, and whether all relevant sites are amenable to local treatment. That is an inference from the response kinetics, TRACE did not test local treatment.

An important question for future trials: how can we identify patients ready for maintenance while recognising those who may benefit from continued T-DXd?

Read the study.”

Title: Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)

Authors: Yukinori Ozaki, Emi Taniguchi, Kazuki Nozawa, Yuka Niwa, Fumikata Hara, Kiyomi Nonogaki, Masahiro Kuno, Yosuke Aoyama, Lina Inagaki, Jun Masuda, Meiko Nishimura, Mami Kurata, Mari Hosonaga, Ippei Fukada, Yuri Kimura, Tetsuyo Maeda, Kazuyo Yoshida, Nami Yamashita, Takayuki Kobayashi, Toshimi Takano, Takayuki Ueno.

You can also read: TALENT Final Results: Neoadjuvant T-DXd Shows Modest Pathologic Activity in HR+/HER2-Low Early Breast Cancer

Kefah Mokbel: When Does Tumour Shrinkage Peak With T-DXd in HER2-Positive Metastatic Breast Cancer?